Merck & Co.
AWARDS
NEWS
THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.
It was another busy week for clinical trial updates and news. Here’s a look.
Merck reported results from two more Phase III trials of V114, it’s 15-valent pneumococcal conjugate vaccine.
New data presented at the IASLC 2020 North America Conference on Lung Cancer shows a combination of Keytruda with other medications has a positive impact on non-small cell lung cancer.
The U.S. Food and Drug Administration has several PDUFA dates for the rest of October, although two of them were already approved. Here’s a look.
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
JOBS
IN THE PRESS